Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Crizanlizumab: First Approval.

Literature DB >> 31933169

Crizanlizumab: First Approval.

Abstract

Crizanlizumab (Adakveo®; crizanlizumab-tmca) is an intravenously administered monoclonal antibody developed by Novartis Pharmaceuticals for the prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease. Crizanlizumab binds to P-selectin, thereby blocking its interaction with P-selectin glycoprotein ligand-1. In November 2019, crizanlizumab received its first global approval in the USA, where it is indicated to reduce the frequency of VOCs in adults and paediatric patients aged ≥ 16 years with sickle cell disease. The drug is also under regulatory review in the EU for the prevention of VOCs in patients with sickle cell disease. The use of crizanlizumab (in combination with ruxolitinib) in myelofibrosis is also being evaluated in Australia, Spain, Germany and Hungary. This article summarizes the milestones in the development of crizanlizumab leading to this first approval for the reduction of VOCs in patients with sickle cell disease.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2020 PMID： 31933169 DOI： 10.1007/s40265-019-01254-2

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

6 in total

1. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.

Authors: Diana R Gutsaeva; James B Parkerson; Shobha D Yerigenahally; Jeffrey C Kurz; Robert G Schaub; Tohru Ikuta; C Alvin Head
Journal: Blood Date: 2010-10-06 Impact factor: 22.113

2. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Authors: Deepa Manwani; Paul S Frenette
Journal: Blood Date: 2013-09-19 Impact factor: 22.113

3. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.

Authors: Kenneth I Ataga; Abdullah Kutlar; Julie Kanter; Darla Liles; Rodolfo Cancado; João Friedrisch; Troy H Guthrie; Jennifer Knight-Madden; Ofelia A Alvarez; Victor R Gordeuk; Sandra Gualandro; Marina P Colella; Wally R Smith; Scott A Rollins; Jonathan W Stocker; Russell P Rother
Journal: N Engl J Med Date: 2016-12-03 Impact factor: 91.245

4. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.

Authors: Abdullah Kutlar; Julie Kanter; Darla K Liles; Ofelia A Alvarez; Rodolfo D Cançado; João R Friedrisch; Jennifer M Knight-Madden; Andreas Bruederle; Michael Shi; Zewen Zhu; Kenneth I Ataga
Journal: Am J Hematol Date: 2018-11-25 Impact factor: 10.047

Review 5. Sickle Cell Disease: Advances in Treatment.

Authors: Renée V Gardner
Journal: Ochsner J Date: 2018

6. Sickle cell disease complications: Prevalence and resource utilization.

Authors: Nirmish Shah; Menaka Bhor; Lin Xie; Jincy Paulose; Huseyin Yuce
Journal: PLoS One Date: 2019-07-05 Impact factor: 3.240

6 in total

13 in total

1. Hematopoietic cell transplantation for sickle cell disease: updates and future directions.

Authors: Lakshmanan Krishnamurti
Journal: Hematology Am Soc Hematol Educ Program Date: 2021-12-10

2. Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models.

Authors: Qiqi Feng; Mengyang Wang; Eldar Muhtar; Yaonan Wang; Haimei Zhu
Journal: Int J Nanomedicine Date: 2021-08-24

3. A pilot clinical phase II trial MemSID: Acute and durable changes of red blood cells of sickle cell disease patients on memantine treatment.

Authors: Asya Mahkro; Inga Hegemann; Elena Seiler; Greta Simionato; Viviana Claveria; Nikolay Bogdanov; Clelia Sasselli; Paul Torgerson; Lars Kaestner; Markus G Manz; Jeroen S Goede; Max Gassmann; Anna Bogdanova
Journal: EJHaem Date: 2020-05-20

4. Elevated P-Selectin in Severe Covid-19: Considerations for Therapeutic Options.

Authors: Chiara Agrati; Veronica Bordoni; Alessandra Sacchi; Nicola Petrosillo; Emanuele Nicastri; Franca Del Nonno; Gianpiero D'Offizi; Fabrizio Palmieri; Luisa Marchioni; Maria Rosaria Capobianchi; Andrea Antinori; Giuseppe Ippolito; Michele Bibas
Journal: Mediterr J Hematol Infect Dis Date: 2021-03-01 Impact factor: 2.576

Review 5. Emerging Roles of Platelets in Allergic Asthma.

Authors: Ming Yue; Mengjiao Hu; Fangda Fu; Hongfeng Ruan; Chengliang Wu
Journal: Front Immunol Date: 2022-04-01 Impact factor: 8.786

Review 6. Endothelial Cell Adhesion Molecules- (un)Attainable Targets for Nanomedicines.

Authors: Nenad Milošević; Marie Rütter; Ayelet David
Journal: Front Med Technol Date: 2022-04-07

Review 7. P- and E- selectin in venous thrombosis and non-venous pathologies.

Authors: Megan Purdy; Andrea Obi; Daniel Myers; Thomas Wakefield
Journal: J Thromb Haemost Date: 2022-03-25 Impact factor: 16.036

Review 8. Emerging roles of platelets in cancer biology and their potential as therapeutic targets.

Authors: Lei Wang; Xueying Wang; Erliang Guo; Xionghui Mao; Susheng Miao
Journal: Front Oncol Date: 2022-07-22 Impact factor: 5.738

9. Aspirin and antiplatelet treatments in cancer.

Authors: Derrick L Tao; Samuel Tassi Yunga; Craig D Williams; Owen J T McCarty
Journal: Blood Date: 2021-06-10 Impact factor: 22.113

10. Efficacy and Tolerance of Vascular Electrical Stimulation Therapy in the Management of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: A Phase II Single-Centre Randomized Study in Ivory Coast.

Authors: Renée-Paule Botti; Sie Saïda Bokoum; Etienne L'Hermite; Dohoma Alexis Silue; Boidy Kouakou; Sarah Anastasie Bognini; Serge Arnaud Agoua; Edgar Mandeng Ma Linwa; Roméo Ayemou; Kouassi Gustave Koffi
Journal: Adv Hematol Date: 2021-02-04